The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

Dupilumab (Dupixent) continues strong growth with €10.7 billion in 2023 sales and $4.34 billion in Q2 2025. FDA approval for COPD in September 2024 and expansion to chronic spontaneous urticaria in children unlock new market opportunities. The drug demonstrates clinical superiority over competitors like Xolair, with market projections extending to 2034 across multiple indications and geographic regions.

Sanofi announced the availability of its aide-mémoire for Q2 2026 results on July 1, 2026, to support financial modeling of quarterly results. The document covers non-comparable items, foreign currency impact, and share count. Full Q2 2026 results will be published on July 30, 2026.

Sanofi has published its Q2 2026 financial aide-mémoire to assist with quarterly financial modeling, with full Q2 2026 results scheduled for July 30, 2026. Additionally, Sanofi's Nexviazyme met all primary and secondary endpoints in a phase 3 study for infantile-onset Pompe disease, representing a significant clinical achievement for the company's pipeline.

Three high-yielding dividend stocks that recently hit 52-week lows are presented as potential bargain opportunities: Sanofi (5.7% yield) despite patent expiration concerns, AT&T (5.3% yield) facing Starlink competition worries, and Vici Properties (6.7% yield) offering stable dividend income. All three trade at attractive valuations with strong dividend coverage.

The Sanofi Foundation announced a strengthened commitment to children and young people facing serious illnesses, climate challenges, and humanitarian crises. With an annual budget of €15 million, the foundation aims to impact over 6 million children and youth by 2030 through partnerships addressing early diagnosis, mental health support, and disease elimination efforts.

The Sanofi Foundation announced a strengthened commitment to children and young people facing serious diseases, climate, and humanitarian challenges. The foundation will allocate €15 million annually for programs benefiting children and youth, with partnerships including the Cerebral Palsy Foundation and AIDA. The foundation aims to impact over 6 million children and young people by 2030, while continuing humanitarian efforts that have reached 26 million patients across 45 countries.

Sanofi announced that Wayrilz (rilzabrutinib), a BTK inhibitor, has received regulatory approval in Japan for treating persistent or chronic immune thrombocytopenia (ITP) in patients who are inadequately responsive to other treatments. The approval is based on the Phase 3 LUNA 3 trial, which demonstrated rapid and sustained platelet response and improved quality of life metrics. Wayrilz is now approved in the US, EU, UAE, UK, and Japan.

Sanofi announced that its drug Wayrilz (rilzabrutinib), a BTK inhibitor, has received marketing authorization in Japan for treating persistent or chronic immune thrombocytopenia (ITP) in patients who don't respond to other treatments. The approval is based on the LUNA 3 phase 3 study, which demonstrated rapid and durable platelet response and improved quality of life compared to placebo.

The European Commission has approved Sanofi's Cenrifki (tolebrutinib), a brain-penetrating Bruton tyrosine kinase inhibitor, for treating secondary progressive multiple sclerosis (SPMS) without relapses. The approval is based on the Phase 3 HERCULES trial, which demonstrated that Cenrifki significantly delayed disability progression. The drug will be commercially available in Germany this year, with careful risk management protocols due to identified hepatic safety concerns.

The European Commission has approved Sanofi's Cenrifki (tolebrutinib) for treating secondary progressive multiple sclerosis without relapses, marking the first disability-targeting therapy for this condition. The approval is based on the HERCULES phase 3 study demonstrating significant delay in disability progression. However, the drug carries identified safety risks including drug-induced liver injury, requiring strict liver monitoring.